Platelet serotonin deficiencies in adults with bleeding problems (Strasbourg)
Platelet Serotonin Deficiencies: the Strasbourg Experience
This project tests whether low serotonin inside platelets is linked to bleeding in adults treated for hemorrhagic syndrome at Strasbourg University Hospital.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT07302087 on ClinicalTrials.gov |
What this trial studies
This is an observational series using second-line platelet tests (dense granule nucleotide and intraplatelet serotonin measurements) performed at the Hemorrhagic Disorders Reference Center in Strasbourg. Tests are done when platelet aggregation in platelet-rich plasma suggests a secretion defect or when clinical signs point to a primary hemostasis problem despite normal von Willebrand factor. The cohort includes adult patients managed at CHU de Strasbourg between January 1, 2023 and April 1, 2024 who consent to additional platelet testing. The goal is to document how often intraplatelet serotonin deficiency occurs, whether it is related to medications, and how it correlates with bleeding and platelet function.
Who should consider this trial
Good fit: Adults (≥18 years) treated at Strasbourg University Hospital for a hemorrhagic syndrome suggesting a primary hemostasis abnormality with normal von Willebrand factor between January 1, 2023 and April 1, 2024 are eligible.
Not a fit: Patients whose bleeding is due to clearly identified non-platelet causes (for example coagulation factor deficiencies or diagnosed von Willebrand disease), those under 18, or those not treated at CHU de Strasbourg are unlikely to benefit from these specific tests.
Why it matters
Potential benefit: If successful, identifying platelet serotonin deficiencies could help explain unexplained bleeding and guide clinicians to adjust medications or pursue targeted management.
How similar studies have performed: Similar investigations of intraplatelet serotonin are limited and findings are preliminary, so the role of platelet serotonin in bleeding remains incompletely documented.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (≥ 18 years old) * Treated at Strasbourg University Hospital for a hemorrhagic syndrome, suggesting a primary hemostasis abnormality and normal von Willebrand factor, during the period from January 1, 2023, to April 1, 2024. Exclusion Criteria: \- Refusal to participate in the study
Where this trial is running
Strasbourg
- Centre de Ressources et de Compétences des Maladies Hémorragiques Constitutionnelles - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Dominique DESPREZ, MD
- Email: dominique.desprez@chru-strasbourg.fr
- Phone: 33 3 88 12 83 71
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.